Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis

BACKGROUND & AIMS: Autoimmune hepatitis (AIH) is a disease of unknown aetiology with a favourable response to immunosuppression. However, in the clinic, it appears that <50% of patients achieve complete response on standard treatment. Serum B cell-activating factor (BAFF) levels are elevated...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JHEP Rep
Hlavní autoři: Arvaniti, Pinelopi, Giannoulis, George, Gabeta, Stella, Zachou, Kalliopi, Koukoulis, George K., Dalekos, George N.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2020
Témata:
Short Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7340979/
https://ncbi.nlm.nih.gov/pubmed/32671332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhepr.2020.100123
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky